NEW YORK (GenomeWeb) — Consumers with a bit of disposable income will soon be able to order their whole-genome sequence from Guardiome, a La Jolla, California-based startup that places a great deal of emphasis on keeping its clients' DNA information private.

Currently in alpha testing, Guardiome has around 50 clients who have tried out the $3,210 service, and the company is hoping to gather feedback from 100 early users. For that price customers receive their genetic code in a secure desktop device, called Helixa, which resembles a four-legged spaceship.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Sponsored by

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.